Video
Dr. Galsky on the “new dawn” in bladder-sparing in bladder cancer
Author(s):
“It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really have the community embrace this as a reasonable option for patients with bladder cancer,” says Matthew Galsky, MD.
Video Player is loading.
In a video filmed during the 2021 ASCO Annual Meeting, Matthew Galsky, MD, discusses the emergence of new bladder-sparing approaches in the treatment of bladder cancer. Galsky is Professor of Medicine (Hematology and Medical Oncology) and Acting Chief of the Division of Hematology and Medical Oncology for the Mount Sinai Health System, New York City, New York.
Related Videos
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
John Gore, MD, on radical cystectomy vs bladder-sparing therapy for NMIBC
Related Content
